JAMA Network Open最新文献

筛选
英文 中文
What to Do When Denosumab Is Stopped? 停用地诺单抗后该怎么办?
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.43879
Nelson B Watts
{"title":"What to Do When Denosumab Is Stopped?","authors":"Nelson B Watts","doi":"10.1001/jamanetworkopen.2024.43879","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2024.43879","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2443879"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Innovation to Inclusion-Tackling Digital Equity Needs in Health Care. 从创新到包容--解决医疗保健中的数字平等需求。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.45334
Sachin D Shah
{"title":"From Innovation to Inclusion-Tackling Digital Equity Needs in Health Care.","authors":"Sachin D Shah","doi":"10.1001/jamanetworkopen.2024.45334","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2024.45334","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2445334"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials. 催产素和液体限制在亚甲二氧基甲基苯丙胺诱发的低钠血症中的作用:对 4 项随机临床试验的二次分析。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.45278
Cihan Atila, Isabelle Straumann, Patrick Vizeli, Julia Beck, Sophie Monnerat, Friederike Holze, Matthias E Liechti, Mirjam Christ-Crain
{"title":"Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials.","authors":"Cihan Atila, Isabelle Straumann, Patrick Vizeli, Julia Beck, Sophie Monnerat, Friederike Holze, Matthias E Liechti, Mirjam Christ-Crain","doi":"10.1001/jamanetworkopen.2024.45278","DOIUrl":"10.1001/jamanetworkopen.2024.45278","url":null,"abstract":"<p><strong>Importance: </strong>3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. Acute hyponatremia is a potentially serious complication after even a single dose of MDMA. The assumed etiology has been a vasopressin release inducing the syndrome of inappropriate antidiuresis combined with increased thirst, causing polydipsia and water intoxication.</p><p><strong>Objective: </strong>To investigate the incidence and severity of hyponatremia after a single dose of MDMA, underlying neuroendocrine mechanisms of action, and the potential effect of fluid restriction on lowering the incidence of hyponatremia.</p><p><strong>Design, setting, and participants: </strong>This ad hoc secondary analysis pooled data from 4 placebo-controlled crossover randomized clinical trials conducted at the University Hospital Basel, Basel, Switzerland. The 96 participants received experimental doses of MDMA between March 1, 2017, and August 31, 2022.</p><p><strong>Intervention: </strong>A single oral 100- or 125-mg dose of MDMA. Fluid intake was not restricted in 81 participants; it was restricted in 15.</p><p><strong>Main outcomes and measures: </strong>Plasma oxytocin, copeptin (marker of vasopressin), and sodium levels were measured repeatedly within 360 minutes after MDMA intake. The association of plasma oxytocin or copeptin levels with plasma sodium level at 180 minutes (peak concentration of MDMA) was determined.</p><p><strong>Results: </strong>Among the 96 participants, the mean (SD) age was 29 (7) years, and 62 (65%) were men. A total of 39 participants (41%) received a 100-mg dose of MDMA, and 57 (59%) received a 125-mg dose. At baseline, the mean (SD) plasma sodium level was 140 (3) mEq/L and decreased in response to MDMA by 3 (3) mEq/L. Hyponatremia occurred in 30 participants (31%) with a mean (SD) sodium level of 133 (2) mEq/L. In 15 participants with restricted fluid intake, no hyponatremia occurred, while in the 81 participants with unrestricted fluid intake, hyponatremia occurred in 30 (37%) (P = .002) with a difference in plasma sodium of 4 (95% CI, 2-5) mEq/L (P < .001) between both groups, suggesting that fluid restriction may mitigate the risk of hyponatremia. At baseline, the mean (SD) plasma oxytocin level was 87 (45) pg/mL and increased in response to MDMA by 388 (297) pg/mL (ie, a mean [SD] 433% [431%] increase at 180 minutes), while the mean (SD) copeptin level was 4.9 (3.8) pmol/L and slightly decreased, by 0.8 (3.0) pmol/L. Change in plasma sodium level from baseline to 180 minutes demonstrated a negative correlation with the changes in oxytocin (R = -0.4; P < .001) and MDMA (R = -0.4; P < .001) levels while showing no correlation with the change in copeptin level.</p><p><strong>Conclusions and relevance: </strong>In this secondary analysis of 4 randomized clinical trials, a high incidence of acute hyponatremia was observed in response to MDMA, which","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2445278"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Board Discipline of Physicians for Spreading Medical Misinformation. 医学委员会对传播医学错误信息的医生进行纪律处分。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.43893
Richard S Saver
{"title":"Medical Board Discipline of Physicians for Spreading Medical Misinformation.","authors":"Richard S Saver","doi":"10.1001/jamanetworkopen.2024.43893","DOIUrl":"10.1001/jamanetworkopen.2024.43893","url":null,"abstract":"<p><strong>Importance: </strong>False medical information disseminated dangerously during the COVID-19 pandemic, with certain physicians playing a surprisingly prominent role. Medical boards engendered widespread criticism for not imposing forceful sanctions, but considerable uncertainty remains about how the professional licensure system regulates physician-spread misinformation.</p><p><strong>Objective: </strong>To compare the level of professional discipline of physicians for spreading medical misinformation relative to discipline for other offenses.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study analyzed and coded publicly reported medical board disciplinary actions in the 5 most populous US states. The analysis included data from January 1, 2020, through May 30, 2023, for California, Florida, New York, and Pennsylvania and from January 1, 2020, through March 30, 2022, for Texas.</p><p><strong>Main outcomes and measures: </strong>Medical board disciplinary proceedings that resulted in some form of sanction were analyzed. Codes were assigned for the different types of offenses relied on by medical boards for imposing physician discipline.</p><p><strong>Results: </strong>Among 3128 medical board disciplinary proceedings in the 5 most populous states, spreading misinformation to the community was the least common reason for medical board discipline of physicians (6 [0.1%] of all identified offenses). Two reasons tied for third least common: patient-directed misinformation (21 [0.3%]) and inappropriate advertising or patient solicitation (21 [0.3%]). The frequency of misinformation conduct was exponentially lower than more common reasons for discipline, such as physician negligence (1911 [28.7%]), problematic record-keeping (990 [14.9%]), and inappropriate prescribing (901 [13.5%]). Patient-directed misinformation provided a basis for discipline 3 times as often as spreading misinformation to the community. The frequency of disciplinary actions for any reasons related to COVID-19 care, even if not about misinformation, was also quite low (10 [0.2%]). Sanctions in misinformation actions tended to be relatively light.</p><p><strong>Conclusions and relevance: </strong>The frequency of discipline for physician-spread misinformation observed in this cross-sectional study was quite low despite increased salience and medical board warnings since the start of the COVID-19 pandemic about the dangers of physicians spreading falsehoods. These findings suggest that there is a serious disconnect between regulatory guidance and enforcement and that medical boards relied on spreading misinformation to patients as a reason for discipline 3 times more frequently than disseminating falsehoods to the public. These results shed light on important policy concerns about professional licensure, including why, under current patient-centered frameworks, this form of regulation may be particularly ill-suited to address medical misinfo","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2443893"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction: A Randomized Clinical Trial. 停用地诺单抗后使用唑来膦酸钠序贯疗法预防骨矿物质密度降低:随机临床试验
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.43899
Chia-Che Lee, Chen-Yu Wang, Hung-Kuan Yen, Chih-Chien Hung, Cheng-Yo Lai, Ming-Hsiao Hu, Ting-Ming Wang, Chung-Yi Li, Shau-Huai Fu
{"title":"Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction: A Randomized Clinical Trial.","authors":"Chia-Che Lee, Chen-Yu Wang, Hung-Kuan Yen, Chih-Chien Hung, Cheng-Yo Lai, Ming-Hsiao Hu, Ting-Ming Wang, Chung-Yi Li, Shau-Huai Fu","doi":"10.1001/jamanetworkopen.2024.43899","DOIUrl":"10.1001/jamanetworkopen.2024.43899","url":null,"abstract":"<p><strong>Importance: </strong>Discontinuation of denosumab without transitioning to another antiresorptive agent results in rapid bone loss and an increased risk of fracture. Previous randomized studies reported inconsistent results regarding the efficacy of zoledronate as sequential therapy.</p><p><strong>Objective: </strong>To investigate the use of sequential therapy with zoledronate to prevent bone loss and decreased bone mineral density (BMD) after denosumab discontinuation in the first year.</p><p><strong>Design, setting, and participants: </strong>The Denosumab Sequential Therapy prospective, open-label, parallel-group randomized clinical trial was conducted at a referral center and 2 affiliated hospitals in Taiwan. Recruitment was conducted from April 1, 2019, to May 31, 2021, and a 2-year follow-up was planned. The trial included postmenopausal women and men aged 50 years or older who received regular denosumab treatment for at least 2 years and did not have previous exposure to other antiosteoporosis medication or meet other exclusion criteria.</p><p><strong>Intervention: </strong>Participants were assigned via stratified randomization to 1 of 2 groups: group A received continuous denosumab treatment (60 mg twice yearly) as the positive control, whereas group ZOL received 1 dose of zoledronate (5 mg) in the first year.</p><p><strong>Main outcomes and measures: </strong>The coprimary outcomes were BMD percentage changes in the lumbar spine (LS-BMD), total hip (TH-BMD), and femoral neck (FN-BMD), respectively. An intention-to-treat analysis was performed.</p><p><strong>Results: </strong>This study included 101 patients (95 women [94.1%]; median age, 72.0 [IQR, 67.0-76.0] years). There were 25 patients in group A (23 women [92.0%]; median age, 74.0 [IQR, 70.0 to 78.0] years) and 76 in group ZOL (72 women [94.7%]; median age, 71.0 [IQR, 65.7 to 76.0] years). In the first year, group ZOL had a significant median decrease in LS-BMD (-0.68% [IQR, -3.22% to 2.75%]) compared with group A (1.30% [IQR, -0.68% to 5.24%]) (P = .03). No significant differences between groups A and ZOL were observed for TH-BMD (median, 1.12% [IQR, -0.06% to 2.25%] vs 0% [-1.47% to 2.15%]) (P = .24) and FN-BMD (median, 0.17% [IQR, -2.29% to 2.90%] vs 0.18% [-2.73% to 3.88%]) (P = .71). We observed a significant difference in the median LS-BMD percentage change for the ZOL subgroup with 3 or more years of denosumab treatment before enrollment (-3.20% [IQR, -7.89% to 0.68%]) compared with group A (1.30% [IQR, -0.68% to 5.24%]) (P = .003).</p><p><strong>Conclusions and relevance: </strong>In this randomized trial of sequential therapy after denosumab discontinuation, bone loss was observed in LS-BMD in the first year among patients receiving zoledronate. A longer duration of denosumab treatment was associated with a further decrease in LS-BMD after zoledronate sequential therapy. Further randomized clinical trials and large-scale studies that investigate the strategies ","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2443899"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma and Memory Function in Children. 儿童哮喘与记忆功能
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.42803
Nicholas J Christopher-Hayes, Sarah C Haynes, Nicholas J Kenyon, Vidya D Merchant, Julie B Schweitzer, Simona Ghetti
{"title":"Asthma and Memory Function in Children.","authors":"Nicholas J Christopher-Hayes, Sarah C Haynes, Nicholas J Kenyon, Vidya D Merchant, Julie B Schweitzer, Simona Ghetti","doi":"10.1001/jamanetworkopen.2024.42803","DOIUrl":"10.1001/jamanetworkopen.2024.42803","url":null,"abstract":"<p><strong>Importance: </strong>Asthma is a chronic respiratory disease affecting approximately 5 million children in the US. Rodent models of asthma indicate memory deficits, but little is known about whether asthma alters children's memory development.</p><p><strong>Objective: </strong>To assess whether childhood asthma is associated with lower memory abilities in children.</p><p><strong>Design, setting, and participants: </strong>This cohort study used observational data from the Adolescent Brain Cognitive Development (ABCD) Study, a multisite longitudinal investigation that began enrollment in 2015. Approximately 11 800 children aged 9 to 10 years were enrolled at baseline with follow-up at 1 and 2 years. Participants were selected based on exposures described subsequently to determine longitudinal and cross-sectional associations between asthma and memory. Data were analyzed from Month year to Month year.</p><p><strong>Exposures: </strong>Asthma was determined from parent reports. For the longitudinal analysis, children were selected if they had asthma at baseline and at the 2-year follow-up (earlier childhood onset), at the 2-year follow-up only (later childhood onset), or no history of asthma. For the cross-sectional analysis, children were selected if they had asthma at any time point, or no history of asthma. The comparison group of children with asthma history was matched on demographic and health covariates for each analysis.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was episodic memory. Secondary outcomes included processing speed, inhibition and attention.</p><p><strong>Results: </strong>Four hundred seventy-four children were included in the longitudinal analysis (earlier childhood onset: 135 children; mean [SD] age, 9.90 [0.63] years; 76 [56%] male; 53 [28%] Black, 29 [21%] Hispanic or Latino, and 91 [48%] White; later childhood onset: 102 children; mean [SD] age 9.88 [0.59] years; 54 [53%] female; 22 [17%] Black, 19 [19%] Hispanic or Latino, and 83 [63%] White; comparison: 237 children; mean [SD] age, 9.89 [0.59] years; 121 [51%] male; 47 [15%] Black, 48 [20%] Hispanic or Latino, and 194 [62%] White). Children with earlier onset of asthma exhibited lower rates of longitudinal memory improvements relative to the comparison group (β = -0.17; 95% CI, -0.28 to -0.05; P = .01). Two thousand sixty-two children were selected for the cross-sectional analysis (with asthma: 1031 children; mean [SD] age, 11.99 [0.66] years; 588 [57%] male; 360 [27%] Black, 186 [18%] Hispanic or Latino, and 719 [54%] White; without asthma: 1031 children; mean [SD] age 12.00 [0.66] years; 477 [54%] female; 273 [21%] Black, 242 [23%] Hispanic or Latino, and 782 [59%] White). Children with asthma (1031 children) showed lower scores on episodic memory (β = -0.09; 95% CI, -0.18 to -0.01; P = .04), processing speed (β = -0.13; 95% CI, -0.22 to -0.03; P = .01), and inhibition and attention (β = -0.11; 95% CI, -0.21 to -0.02; P = .02).</p","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2442803"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023. 美国成人呼吸道合胞病毒相关住院负担,2016 年 10 月至 2023 年 9 月。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.44756
Fiona P Havers, Michael Whitaker, Michael Melgar, Huong Pham, Shua J Chai, Elizabeth Austin, James Meek, Kyle P Openo, Patricia A Ryan, Chloe Brown, Kathryn Como-Sabetti, Daniel M Sosin, Grant Barney, Brenda L Tesini, Melissa Sutton, H Keipp Talbot, Ryan Chatelain, Pam Daily Kirley, Isaac Armistead, Kimberly Yousey-Hindes, Maya L Monroe, Val Tellez Nunez, Ruth Lynfield, Chelsea L Esquibel, Kerianne Engesser, Kevin Popham, Arilene Novak, William Schaffner, Tiffanie M Markus, Ashley Swain, Monica E Patton, Lindsay Kim
{"title":"Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.","authors":"Fiona P Havers, Michael Whitaker, Michael Melgar, Huong Pham, Shua J Chai, Elizabeth Austin, James Meek, Kyle P Openo, Patricia A Ryan, Chloe Brown, Kathryn Como-Sabetti, Daniel M Sosin, Grant Barney, Brenda L Tesini, Melissa Sutton, H Keipp Talbot, Ryan Chatelain, Pam Daily Kirley, Isaac Armistead, Kimberly Yousey-Hindes, Maya L Monroe, Val Tellez Nunez, Ruth Lynfield, Chelsea L Esquibel, Kerianne Engesser, Kevin Popham, Arilene Novak, William Schaffner, Tiffanie M Markus, Ashley Swain, Monica E Patton, Lindsay Kim","doi":"10.1001/jamanetworkopen.2024.44756","DOIUrl":"10.1001/jamanetworkopen.2024.44756","url":null,"abstract":"<p><strong>Importance: </strong>Respiratory syncytial virus (RSV) infection can cause severe illness in adults. However, there is considerable uncertainty in the burden of RSV-associated hospitalizations among adults prior to RSV vaccine introduction.</p><p><strong>Objective: </strong>To describe the demographic characteristics of adults hospitalized with laboratory-confirmed RSV and to estimate annual rates and numbers of RSV-associated hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study used data from the RSV Hospitalization Surveillance Network (RSV-NET), a population-based surveillance platform that captures RSV-associated hospitalizations in 58 counties in 12 states, covering approximately 8% of the US population. The study period spanned 7 surveillance seasons from 2016-2017 through 2022-2023. Included cases from RSV-NET were nonpregnant hospitalized adults aged 18 years or older residing in the surveillance catchment area and with a positive RSV test result.</p><p><strong>Exposure: </strong>Laboratory-confirmed RSV-associated hospitalization, defined as a positive RSV test result within 14 days before or during hospitalization.</p><p><strong>Main outcomes and measures: </strong>Hospitalization rates per 100 000 adult population, stratified by age group. After adjusting for test sensitivity and undertesting for RSV in adults hospitalized with acute respiratory illnesses, rates were extrapolated to the US population to estimate annual numbers of RSV-associated hospitalizations. Clinical outcome data were used to estimate RSV-associated ICU admissions and in-hospital deaths.</p><p><strong>Results: </strong>From the 2016 to 2017 through the 2022 to 2023 RSV seasons, there were 16 575 RSV-associated hospitalizations in adults (median [IQR] age, 70 [58-81] years; 9641 females [58.2%]). Excluding the 2020 to 2021 and the 2021 to 2022 seasons, when the COVID-19 pandemic affected RSV circulation, hospitalization rates ranged from 48.9 (95% CI, 33.4-91.5) per 100 000 adults in 2016 to 2017 to 76.2 (95% CI, 55.2-122.7) per 100 000 adults in 2017 to 2018. Rates were lowest among adults aged 18 to 49 years (8.6 [95% CI, 5.7-16.8] per 100 000 adults in 2016-2017 to 13.1 [95% CI, 11.0-16.1] per 100 000 adults in 2022-2023) and highest among adults 75 years or older (244.7 [95% CI, 207.9-297.3] per 100 000 adults in 2022-2023 to 411.4 [95% CI, 292.1-695.4] per 100 000 adults in 2017-2018). Annual hospitalization estimates ranged from 123 000 (95% CI, 84 000-230 000) in 2016 to 2017 to 193 000 (95% CI, 140 000-311 000) in 2017 to 2018. Annual ICU admission estimates ranged from 24 400 (95% CI, 16 700-44 800) to 34 900 (95% CI, 25 500-55 600) for the same seasons. Estimated annual in-hospital deaths ranged from 4680 (95% CI, 3570-6820) in 2018 to 2019 to 8620 (95% CI, 6220-14 090) in 2017 to 2018. Adults 75 years or older accounted for 45.6% (ran","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2444756"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Incidence and Age Eligibility for Elementary School. COVID-19 发病率和小学入学年龄资格。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.44836
Eve Lin, Alyssa Bilinski, Philip A Collender, Vivian Lee, Sohil R Sud, Tomás M León, Lauren A White, Justin V Remais, Jennifer R Head
{"title":"COVID-19 Incidence and Age Eligibility for Elementary School.","authors":"Eve Lin, Alyssa Bilinski, Philip A Collender, Vivian Lee, Sohil R Sud, Tomás M León, Lauren A White, Justin V Remais, Jennifer R Head","doi":"10.1001/jamanetworkopen.2024.44836","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2024.44836","url":null,"abstract":"<p><strong>Importance: </strong>Understanding the role of school attendance on transmission of SARS-CoV-2 among children is of importance for responding to future epidemics. Estimating discontinuities in outcomes by age of eligibility for school attendance has been used to examine associations between school attendance and a variety of outcomes, but has yet to be applied to describe associations between school attendance and communicable disease transmission.</p><p><strong>Objective: </strong>To estimate the association between eligibility for elementary school and COVID-19 incidence.</p><p><strong>Design, setting, and participants: </strong>This case series used data on all pediatric COVID-19 cases reported to California's disease surveillance system between May 16, 2020, and December 15, 2022, among children within 24 months of the age threshold for school eligibility.</p><p><strong>Exposure: </strong>Birthdate before or after the age threshold for elementary school eligibility during periods when school was remote vs in person.</p><p><strong>Main outcomes and measures: </strong>COVID-19 cases and hospitalizations.</p><p><strong>Results: </strong>Between May 16, 2020, and December 15, 2022, there were 688 278 cases of COVID-19 (348 957 cases [50.7%] among boys) and 1423 hospitalizations among children who turned 5 years within 24 months of September 1 of the school year when their infection occurred. The mean (SD) age of the study sample was 5.0 (1.3) years. After adjusting for higher rates of testing in schooled populations, the estimated pooled incidence rate ratio among kindergarten-eligible individuals (eg, those born just before the age threshold for school eligibility) compared with those born just after the eligibility threshold for in-person fall 2021 semester was 1.52 (95% CI, 1.36-1.68), for in-person spring 2022 semester was 1.26 (95% CI, 1.15-1.39), and for in-person fall 2022 semester was 1.19 (95% CI, 1.03-1.38). Reported incidence rates among school-eligible children remained higher during the month-long winter 2021-2022 school break but were lower during the longer summer break that followed. The findings were unable to establish whether associations between school eligibility and COVID-19 incidence were based on in-school vs out-of-school routes (eg, classrooms vs school buses). The study lacked power to detect associations between school attendance and hospitalization. Results were robust to functional form. A simulation study was conducted to demonstrate bias associated with nonadjustment for differential case acquisition by exposure status.</p><p><strong>Conclusions and relevance: </strong>In this case series of children in California, the magnitude of the association between school eligibility and COVID-19 incidence decreased over time and was generally lower than other published associations between out-of-school child social interactions and COVID-19 incidence. This regression discontinuity design approach could be adapte","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2444836"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prenatal Diet and Infant Growth From Birth to Age 24 Months. 产前饮食与婴儿从出生到 24 个月的生长发育。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.45771
Monique M Hedderson, Holly B Schuh, Emily A Knapp, Traci A Bekelman, Diane J Catellier, Matt Westlake, Kristen Lyall, Rebecca J Schmidt, Anne L Dunlop, Sarah S Comstock, Leda Chatzi, Katherine A Sauder, Dana Dabelea, Karen M Switkowski, Pi-I Debby Lin, Lyndsay A Avalos, Yeyi Zhu, Assiamira Ferrara
{"title":"Prenatal Diet and Infant Growth From Birth to Age 24 Months.","authors":"Monique M Hedderson, Holly B Schuh, Emily A Knapp, Traci A Bekelman, Diane J Catellier, Matt Westlake, Kristen Lyall, Rebecca J Schmidt, Anne L Dunlop, Sarah S Comstock, Leda Chatzi, Katherine A Sauder, Dana Dabelea, Karen M Switkowski, Pi-I Debby Lin, Lyndsay A Avalos, Yeyi Zhu, Assiamira Ferrara","doi":"10.1001/jamanetworkopen.2024.45771","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2024.45771","url":null,"abstract":"<p><strong>Importance: </strong>Being born either small for gestational age (SGA) or large for gestational age (LGA) and experiencing rapid or slow growth after birth are associated with later-life obesity. Understanding the associations of dietary quality during pregnancy with infant growth may inform obesity prevention strategies.</p><p><strong>Objective: </strong>To evaluate the associations of prenatal dietary quality according to the Healthy Eating Index (HEI) and the Empirical Dietary Inflammatory Pattern (EDIP) with infant size at birth and infant growth from birth to age 24 months.</p><p><strong>Design, setting, and participants: </strong>This cohort study used data from birthing parent-child dyads in 8 cohorts participating in the Environmental influences on Child Health Outcomes program between 2007 and 2021. Data were analyzed from March 2021 to August 2024.</p><p><strong>Exposures: </strong>The HEI and the EDIP dietary patterns.</p><p><strong>Main outcomes and measures: </strong>Outcomes of interest were infant birth weight, categorized as SGA, reference range, or LGA, and infant growth from birth to ages 6, 12, and 24 months, categorized as slow growth (weight-for-length z score [WLZ] score difference <-0.67), within reference range (WLZ score difference -0.67 to 0.67), or rapid (WLZ score difference, >0.67).</p><p><strong>Results: </strong>The study included 2854 birthing parent-child dyads (median [IQR] maternal age, 30 [25-34] years; 1464 [51.3%] male infants). The cohort was racially and ethnically diverse, including 225 Asian or Pacific Islander infants (7.9%), 640 Black infants (22.4%), 1022 Hispanic infants (35.8%), 664 White infants (23.3%), and 224 infants (7.8%) with other race or multiple races. A high HEI score (>80), indicative of a healthier diet, was associated with lower odds of LGA (adjusted odds ratio [aOR], 0.88 [95% CI, 0.79-0.98]), rapid growth from birth to age 6 months (aOR, 0.80 [95% CI, 0.37-0.94]) and age 24 months (aOR 0.82 [95% CI, 0.70- 0.96]), and slow growth from birth to age 6 months (aOR, 0.65 [95% CI, 0.50-0.84]), 12 months (aOR, 0.74 [95% CI, 0.65-0.83]), and 24 months (OR, 0.65 [95% CI, 0.56-0.76]) compared with an HEI score 80 or lower. There was no association between high HEI and SGA (aOR, 1.14 [95% CI, 0.95-1.35]). A low EDIP score (ie, ≤63.6), indicative of a less inflammatory diet, was associated with higher odds of LGA (aOR, 1.24 [95% CI, 1.13-1.36]) and rapid infant growth from birth to age 12 months (aOR, 1.50 [95% CI, 1.18-1.91]) and lower odds of rapid growth to age 6 months (aOR, 0.77 [95% CI, 0.71-0.83]), but there was no association with SGA (aOR, 0.80 [95% CI, 0.51-1.25]) compared with an EDIP score of 63.6 or greater.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, a prenatal diet that aligned with the US Dietary Guidelines was associated with reduced patterns of rapid and slow infant growth, known risk factors associated with obesity. Future research should ","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2445771"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinician Distribution and Type in Rural and Urban Areas of the National Health Services Corps. 国家卫生服务团城乡地区临床医生的分布和类型。
IF 10.5 1区 医学
JAMA Network Open Pub Date : 2024-11-04 DOI: 10.1001/jamanetworkopen.2024.45995
Olesya Baker, Marcela Horvitz-Lennon, Hao Yu
{"title":"Clinician Distribution and Type in Rural and Urban Areas of the National Health Services Corps.","authors":"Olesya Baker, Marcela Horvitz-Lennon, Hao Yu","doi":"10.1001/jamanetworkopen.2024.45995","DOIUrl":"10.1001/jamanetworkopen.2024.45995","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2445995"},"PeriodicalIF":10.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信